Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity

Advances in Immunology

Volumn 90, Issue , 2006, Pages 1-50

  Smyth, Mark J ^a   Dunn, Gavin P ^b   Schreiber, Robert D ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER CONTROL; CANCER INHIBITION; CELL SURVIVAL; CELL TRANSFORMATION; CELLULAR IMMUNITY; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEUKOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOSUPPRESSION; MONITORING, IMMUNOLOGIC; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 33646755569     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(06)90001-7     Document Type: Review

References (275)

1. Affabris E., Romeo G., Federico M., Coccia E., Locardi C., Belardelli F., and Rossi G.B. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. Haematologica 72 (1987) 76-78
2. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Tsujimura K., Kuzushima K., Takahashi T., Azuma I., Akira S., Toyoshima K., and Seya T. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res. 64 (2004) 757-764
3. Albert M.L., Austin L.M., and Darnell R.B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47 (2000) 9-17
4. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., and Darnell R.B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4 (1998) 1321-1324
5. Albert M.L., and Darnell R.B. Paraneoplastic neurological degenerations: Keys to tumour immunity. Nat. Rev. Cancer 4 (2004) 36-44
6. Algarra I., Cabrera T., and Garrido F. The HLA crossroad in tumor immunology. Hum. Immunol. 61 (2000) 65-73
7. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., and Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
8. Bach E.A., Aguet M., and Schreiber R.D. The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15 (1997) 563-591
9. Bancroft G.J., Schreiber R.D., and Unanue E.R. Natural immunity: A T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol. Rev. 124 (1991) 5-24
10. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
11. Baxevanis C.N., Voutsas I.F., Tsitsilonis O.E., Tsiatas M.L., Gritzapis A.D., and Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur. J. Immunol. 30 (2000) 1957-1966
12. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002) 119-134
13. Blasius A., Vermi W., Krug A., Facchetti F., Cella M., and Colonna M. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood 103 (2004) 4201-4206
14. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183 (1996) 725-729
15. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., Maruyama K., Wakasugi H., Angevin E., Thielemans K., Le Cesne A., Chung-Scott V., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114 (2004) 379-388
16. Boshoff C., and Weiss R. AIDS-related malignancies. Nat. Rev. Cancer 2 (2002) 373-382
17. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., and Darnell Jr. J.E. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93 (1996) 7673-7678
18. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., and Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96 (2000) 3838-3846
19. Burnet F.M. Immunological factors in the process of carcinogenesis. Br. Med. Bull. 20 (1964) 154-158
20. Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13 (1970) 1-27
21. Burnet F.M. Immunological surveillance in neoplasia. Transplant Rev. 7 (1971) 3-25
22. Burnet M. Cancer: A biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1 (1957) 841-847
23. Burstein N.A., and Law L.W. Neonatal thymectomy and non-viral mammary tumours in mice. Nature 231 (1971) 450-452
24. Carayannopoulos L.N., Naidenko O.V., Fremont D.H., and Yokoyama W.M. Cutting edge: Murine UL16-binding protein-like transcript 1: A newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169 (2002) 4079-4083
25. Carey T.E., Takahashi T., Resnick L.A., Oettgen H.F., and Old L.J. Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 73 (1976) 3278-3282
26. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
27. Cerwenka A., Baron J.L., and Lanier L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 11521-11526
28. Cerwenka A., and Lanier L.L. Ligands for natural killer cell receptors: Redundancy or specificity. Immunol. Rev. 181 (2001) 158-169
29. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., and Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94 (1997) 1914-1918
30. Chin Y.E., Kitagawa M., Kuida K., Flavell R.A., and Fu X.Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17 (1997) 5328-5337
31. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., and Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 (1996) 719-722
32. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996) 1303-1310
33. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., Martos J.A., and Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79 (1997) 2320-2328
34. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases 1893. Clin. Orthop. 262 (1991) 3-11
35. Conejo-Garcia J.R., Benencia F., Courreges M.C., Kang E., Mohamed-Hadley A., Buckanovich R.J., Holtz D.O., Jenkins A., Na H., Zhang L., Wagner D.S., Katsaros D., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10 (2004) 950-958
36. Conejo-Garcia J.R., Benencia F., Courreges M.C., Khang E., Zhang L., Mohamed-Hadley A., Vinocur J.M., Buckanovich R.J., Thompson C.B., Levine B., and Coukos G. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol. Ther. 2 (2003) 446-451
37. Cory S., Huang D.C., and Adams J.M. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 22 (2003) 8590-8607
38. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., Kubin M., and Chalupny N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 (2001) 123-133
39. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., Gri G., Wysocka M., Kim J.E., Liu L., Liao F., Farber J.M., et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34
40. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
41. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196 (2002) 119-127
42. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., and Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278 (1997) 1623-1626
43. Cui Z., Willingham M.C., Hicks A.M., Alexander-Miller M.A., Howard T.D., Hawkins G.A., Miller M.S., Weir H.M., Du W., and DeLong C.J. Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Proc. Natl. Acad. Sci. USA 100 (2003) 6682-6687
44. Curcio C., Di Carlo E., Clynes R., Smyth M.J., Boggio K., Quaglino E., Spadaro M., Colombo M.P., Amici A., Lollini P.L., Musiani P., and Forni G. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111 (2003) 1161-1170
45. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
46. Danial N.N., and Korsmeyer S.J. Cell death: Critical control points. Cell 116 (2004) 205-219
47. Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA 93 (1996) 4529-4536
48. Darnell R.B., and DeAngelis L.M. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341 (1993) 21-22
49. Darnell R.B., and Posner J.B. Observing the invisible: Successful tumor immunity in humans. Nat. Immunol. 4 (2003) 201
50. Das H., Groh V., Kuijl C., Sugita M., Morita C.T., Spies T., and Bukowski J.F. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15 (2001) 83-93
51. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., Miller T.P., LeBlanc M., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351 (2004) 2159-2169
52. Davidson W.F., Giese T., and Fredrickson T.N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187 (1998) 1825-1838
53. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., and Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197 (2003) 1667-1676
54. Di Carlo E., Forni G., Lollini P., Colombo M.P., Modesti A., and Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97 (2001) 339-345
55. Diefenbach A., Hsia J.K., Hsiung M.Y., and Raulet D.H. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33 (2003) 381-391
56. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., and Raulet D.H. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1 (2000) 119-126
57. Diefenbach A., Jensen E.R., Jamieson A.M., and Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
58. Dighe A.S., Richards E., Old L.J., and Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456
59. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
60. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., Diamond M.S., Koebel C.M., Arthur C., White J.M., and Schreiber R.D. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6 (2005) 722-729
61. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
62. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004) 329-360
63. Dunn G.P., Sheehan K.C., Old L.J., and Schreiber R.D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65 (2005) 3447-3453
64. Ehrlich P. Uber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Genees. 5 (1909) 273-290
65. Elder G.J., Hersey P., and Branley P. Remission of transplanted melanoma-clinical course and tumour cell characterisation. Clin. Transplant. 11 (1997) 565-568
66. Engel A.M., Svane I.M., Mouritsen S., Rygaard J., Clausen J., and Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. Apmis 104 (1996) 629-639
67. Enzler T., Gillessen S., Manis J.P., Ferguson D., Fleming J., Alt F.W., Mihm M., and Dranoff G. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med. 197 (2003) 1213-1219
68. Erianne G.S., Wajchman J., Yauch R., Tsiagbe V.K., Kim B.S., and Ponzio N.M. B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth. Leuk. Res. 24 (2000) 705-718
69. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
70. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004) 941-952
71. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., and Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
72. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., and Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5 (1999) 2963-2970
73. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., Craft J., and Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198 (2003) 433-442
74. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
75. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., and Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195 (2002) 327-333
76. Gershwin M.E., Ohsugi Y., Castles J.J., Ikeda R.M., and Ruebner B. Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice. J. Immunol. 131 (1983) 2069-2073
77. Gilfillan S., Ho E.L., Cella M., Yokoyama W.M., and Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3 (2002) 1150-1155
78. Girardi M., Glusac E., Filler R.B., Roberts S.J., Propperova I., Lewis J., Tigelaar R.E., and Hayday A.C. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198 (2003) 747-755
79. Girardi M., Oppenheim D., Glusac E.J., Filler R., Balmain A., Tigelaar R.E., and Hayday A.C. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J. Invest. Dermatol. 122 (2004) 699-706
80. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., and Hayday A.C. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (2001) 605-609
81. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: Facts, functions and fallacies. Immunol. Today 21 (2000) 573-583
82. Godfrey D.I., Pellicci D.G., and Smyth M.J. Immunology. The elusive NKT cell antigen-is the search over?. Science 306 (2004) 1687-1689
83. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 (2001) 1118-1122
84. Gorelik L., and Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2 (2002) 46-53
85. Grant G.A., and Miller J.F. Effect of neonatal thymectomy on the induction of sarcomata in C57 BL mice. Nature 205 (1965) 1124-1125
86. Graus F., Dalmou J., Rene R., Tora M., Malats N., Verschuuren J.J., Cardenal F., Vinolas N., Garcia del Muro J., Vadell C., Mason W.P., Rosell R., et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J. Clin. Oncol. 15 (1997) 2866-2872
87. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
88. Gresser I., and Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 13 (2002) 111-118
89. Gresser I., Belardelli F., Maury C., Maunoury M.T., and Tovey M.G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158 (1983) 2095-2107
90. Gresser I., Maury C., Vignaux F., Haller O., Belardelli F., and Tovey M.G. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J. Exp. Med. 168 (1988) 1271-1291
91. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93 (1996) 12445-12450
92. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., and Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2 (2001) 255-260
93. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96 (1999) 6879-6884
94. Groh V., Steinle A., Bauer S., and Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279 (1998) 1737-1740
95. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
96. Hahn W.C., and Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2 (2002) 331-441
97. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., and Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274 (1996) 1363-1366
98. Haliotis T., Ball J.K., Dexter D., and Roder J.C. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int. J. Cancer 35 (1985) 505-513
99. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
100. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
101. Hayakawa Y., Godfrey D.I., and Smyth M.J. Alpha-galactosylceramide: Potential immunomodulatory activity and future application. Curr. Med. Chem. 11 (2004) 241-252
102. Hayakawa Y., Kelly J.M., Westwood J.A., Darcy P.K., Diefenbach A., Raulet D., and Smyth M.J. Cutting edge: Tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169 (2002) 5377-5381
103. Hayakawa Y., Rovero S., Forni G., and Smyth M.J. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 9464-9469
104. Hayashi T., and Faustman D.L. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res. 62 (2002) 24-27
105. Heidelberger C. Chemical carcinogenesis. Annu. Rev. Biochem. 44 (1975) 79-121
106. Hodge-Dufour J., Noble P.W., Horton M.R., Bao C., Wysoka M., Burdick M.D., Strieter R.M., Trinchieri G., and Pure E. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J. Immunol. 159 (1997) 2492-2500
107. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
108. Humbert P., Russell S., and Richardson H. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays 25 (2003) 542-553
109. Hunig T., and Bevan M.J. Specificity of cytotoxic T cells from athymic mice. J. Exp. Med. 152 (1980) 688-702
110. Iinuma T., Homma S., Noda T., Kufe D., Ohno T., and Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest. 113 (2004) 1307-1317
111. Ikehara S., Pahwa R.N., Fernandes G., Hansen C.T., and Good R.A. Functional T cells in athymic nude mice. Proc. Natl. Acad. Sci. USA 81 (1984) 886-888
112. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., and Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88 (2000) 577-583
113. Jan Chalupny N., Sutherland C.L., Lawrence W.A., Rein-Weston A., and Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305 (2003) 129-135
114. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54 Pt. 1 (1989) 1-13
115. Jinushi M., Takehara T., Kanto T., Tatsumi T., Groh V., Spies T., Miyagi T., Suzuki T., Sasaki Y., and Hayashi N. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: Impairment in chronic hepatitis C virus infection. J. Immunol. 170 (2003) 1249-1256
116. Jinushi M., Takehara T., Tatsumi T., Kanto T., Groh V., Spies T., Kimura R., Miyagi T., Mochizuki K., Sasaki Y., and Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer 104 (2003) 354-361
117. Johnson G.B., Brunn G.J., Kodaira Y., and Platt J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168 (2002) 5233-5239
118. Johnson S. Effect of thymectomy on the induction of skin tumours by dibenzanthracene, and of breast tumours by dimethylbenzanthracene, in mice of the IF strain. Br. J. Cancer 22 (1968) 755-761
119. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998) 7556-7561
120. Kaplan H.S. Role of immunologic disturbance in human oncogenesis: Some facts and fancies. Br. J. Cancer 25 (1971) 620-634
121. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3 (2002) 999-1005
122. Klein G. Tumor antigens. Annu. Rev. Microbiol. 20 (1966) 223-252
123. Klein G. Immunological surveillance against neoplasia. Harvey Lect. 69 (1973) 71-102
124. Knight B., Yeoh G.C., Husk K.L., Ly T., Abraham L.J., Yu C., Rhim J.A., and Fausto N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 192 (2000) 1809-1818
125. Knuth A., Danowski B., Oettgen H.F., and Old L.J. T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA 81 (1984) 3511-3515
126. Kumar A., Commane M., Flickinger T.W., Horvath C.M., and Stark G.R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278 (1997) 1630-1632
127. Lala P.K., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2 (2001) 149-156
128. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., McGarry M.P., O'Neill K.R., Protheroe C., Pero R., Nguyen T., Cormier S.A., Lenkiewicz E., Colbert D., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 (2004) 1773-1776
129. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
130. Li Z., Menoret A., and Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr. Opin. Immunol. 14 (2002) 45-51
131. Liljefors M., Nilsson B., Hjelm Skog A.L., Ragnhammar P., Mellstedt H., and Frodin J.E. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int. J. Cancer 105 (2003) 717-723
132. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S., and Linehan D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169 (2002) 2756-2761
133. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104 (2001) 487-501
134. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51 (1991) 3075-3079
135. Loeb L.A., Loeb K.R., and Anderson J.P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100 (2003) 776-781
136. Loeffler C.M., Smyth M.J., Longo D.L., Kopp W.C., Harvey L.K., Tribble H.R., Tase J.E., Urba W.J., Leonard A.S., Young H.A., et al. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol. 149 (1992) 949-956
137. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
138. Ludwig A.T., Moore J.M., Luo Y., Chen X., Saltsgaver N.A., O'Donnell M.A., and Griffith T.S. Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 64 (2004) 3386-3390
139. Luster A.D., and Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178 (1993) 1057-1065
140. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
141. MacKie R.M., Reid R., and Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348 (2003) 567-568
142. Macleod K. Tumor suppressor genes. Curr. Opin. Genet. Dev. 10 (2000) 81-93
143. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15 (1997) 323-350
144. Maleckar J.R., and Sherman L.A. The composition of the T cell receptor repertoire in nude mice. J. Immunol. 138 (1987) 3873-3876
145. Marincola F.M., Jaffee E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
146. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., and Parish C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process. J. Exp. Med. 197 (2003) 387-393
147. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994) 991-1045
148. Medawar P. The behaviour and fate of skin autografts and skin homografts in rabbits. J. Anat. 78 (1944) 176-199
149. Melani C., Chiodoni C., Forni G., and Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102 (2003) 2138-2145
150. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
151. Mihm Jr. M.C., Mihm C.G., and Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74 (1996) 43-47
152. Mitra-Kaushik S., Harding J., Hess J., Schreiber R., and Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood 104 (2004) 3305-3311
153. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., Kollias G., and Balkwill F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5 (1999) 828-831
154. Musunuru K., and Darnell R.B. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu. Rev. Neurosci. 24 (2001) 239-262
155. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., and Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998) 3491-3494
156. Nakata M., Smyth M.J., Norihisa Y., Kawasaki A., Shinkai Y., Okumura K., and Yagita H. Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: Implication for their cytotoxic role in vivo. J. Exp. Med. 172 (1990) 1877-1880
157. Natarajan K., Dimasi N., Wang J., Margulies D.H., and Mariuzza R.A. MHC class I recognition by Ly49 natural killer cell receptors. Mol. Immunol. 38 (2002) 1023-1027
158. Nishikawa H., Kato T., Tanida K., Hiasa A., Tawara I., Ikeda H., Ikarashi Y., Wakasugi H., Kronenberg M., Nakayama T., Taniguchi M., Kuribayashi K., et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100 (2003) 10902-10906
159. Noguchi Y., Jungbluth A., Richards E.C., and Old L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA 93 (1996) 11798-11801
160. Nomoto K., and Takeya K. Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice. J. Natl. Cancer Inst. 42 (1969) 445-453
161. Nomura M., Takihara Y., and Shimada K. Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: One of the early inducible clones encodes a novel protein sharing several highly homologous regions with a Drosophila polyhomeotic protein. Differentiation 57 (1994) 39-50
162. O'Hanlon L.H. Natural born killers: NK cells drafted into the cancer fight. J. Natl. Cancer Inst. 96 (2004) 651-653
163. Odunsi K. Lessons from a pilot clinical trial of vaccine therapy with an NY-ESO-1 peptide of dual MHC class I and II specificites in ovarian cancer. Cancer Immun. 5 (2005) S22
164. Okamoto M., Ahmed S.U., Oshikawa T., Tano T., and Sato M. [Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432]. Gan To Kagaku Ryoho 31 (2004) 1627-1630
165. Old L.J. Cancer immunology: The search for specificity-G. H. A. Clowes Memorial lecture. Cancer Res. 41 (1981) 361-375
166. Old L.J. Cancer vaccines 2003: Opening address. Cancer Immun. 3 Suppl. 2 (2003) 1
167. Old L.J., and Boyse E.A. Immunology of experimental tumors. Annu. Rev. Med. 15 (1964) 167-186
168. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., and Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59 (1999) 3128-3133
169. Oppenheim D.E., Roberts S.J., Clarke S.L., Filler R., Lewis J.M., Tigelaar R.E., Girardi M., and Hayday A.C. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6 (2005) 928-937
170. Outzen H.C., Custer R.P., Eaton G.J., and Prehn R.T. Spontaneous and induced tumor incidence in germfree "nude" mice. J. Reticuloendothel. Soc. 17 (1975) 1-9
171. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
172. Pende D., Rivera P., Marcenaro S., Chang C.C., Biassoni R., Conte R., Kubin M., Cosman D., Ferrone S., Moretta L., and Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62 (2002) 6178-6186
173. Peng S.L., Robert M.E., Hayday A.C., and Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184 (1996) 1149-1154
174. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 61 (1996) 274-278
175. Penn I., and Starzl T.E. Malignant lymphomas in transplantation patients: A review of the world experience. Int. Z. Klin. Pharmakol. Ther. Toxikol. 3 (1970) 49-54
176. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004) 8-32
177. Peter M.E., and Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10 (2003) 26-35
178. Qin Z., and Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12 (2000) 677-686
179. Radosavljevic M., Cuillerier B., Wilson M.J., Clement O., Wicker S., Gilfillan S., Beck S., Trowsdale J., and Bahram S. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 79 (2002) 114-123
180. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002) 826-835
181. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3 (2003) 781-790
182. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 (1999) 281-287
183. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., and Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
184. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., and Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
185. Rygaard J., and Povlsen C.O. Is immunological surveillance not a cell-mediated immune function?. Transplantation 17 (1974) 135-136
186. Rygaard J., and Povlsen C.O. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol. Microbiol. Scand. [B] Microbiol. Immunol. 82 (1974) 99-106
187. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995) 11810-11813
188. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 101 (2000) 455-458
189. Sakaguchi S. Immunologic tolerance maintained by regulatory T cells: Implications for autoimmunity, tumor immunity and transplantation tolerance. Vox Sang. 83 Suppl. 1 (2002) 151-153
190. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
191. Salih H.R., Rammensee H.G., and Steinle A. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169 (2002) 4098-4102
192. Sallusto F., Mackay C.R., and Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18 (2000) 593-620
193. Sanford B.H., Kohn H.I., Daly J.J., and Soo S.F. Long-term spontaneous tumor incidence in neonatally thymectomized mice. J. Immunol. 110 (1973) 1437-1439
194. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
195. Schmaltz C., Alpdogan O., Kappel B.J., Muriglan S.J., Rotolo J.A., Ongchin J., Willis L.M., Greenberg A.S., Eng J.M., Crawford J.M., Murphy G.F., Yagita H., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8 (2002) 1433-1437
196. Schreiber R.D., Old L.J., Hayday A.C., and Smyth M.J. Response to "A cancer immunosurveillance controversy.". Nat. Immunol. 5 (2004) 4-5
197. Schreiber R.D., Pace J.L., Russell S.W., Altman A., and Katz D.H. Macrophage-activating factor produced by a T cell hybridoma: Physiochemical and biosynthetic resemblance to gamma-interferon. J. Immunol. 131 (1983) 826-832
198. Schumacher K., Haensch W., Roefzaad C., and Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61 (2001) 3932-3936
199. Seifried H.E., McDonald S.S., Anderson D.E., Greenwald P., and Milner J.A. The antioxidant conundrum in cancer. Cancer Res. 63 (2003) 4295-4298
200. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 (2000) 455-464
201. Seong S.Y., and Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4 (2004) 469-478
202. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
203. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
204. Shevach E.M. CD4+ CD25+ suppressor T cells: More questions than answers. Nat. Rev. Immunol. 2 (2002) 389-400
205. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
206. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
207. Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68 (1992) 855-867
208. Smyth M.J. Type I interferon and cancer immunoediting. Nat. Immunol. 6 (2005) 646-648
209. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., and Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193 (2001) 661-670
210. Smyth M.J., Crowe N.Y., and Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13 (2001) 459-463
211. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., and Godfrey D.I. NKT cells-conductors of tumor immunity?. Curr. Opin. Immunol. 14 (2002) 165-171
212. Smyth M.J., and Godfrey D.I. NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1 (2000) 459-460
213. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2 (2001) 293-299
214. Smyth M.J., Kelly J.M., Baxter A.G., Korner H., and Sedgwick J.D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 188 (1998) 1611-1619
215. Smyth M.J., Ortaldo J.R., Shinkai Y., Yagita H., Nakata M., Okumura K., and Young H.A. Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells. J. Exp. Med. 171 (1990) 1269-1281
216. Smyth M.J., Street S.E., and Trapani J.A. Cutting edge: Granzymes A and B are not essential for perforin-mediated tumor rejection. J. Immunol. 171 (2003) 515-518
217. Smyth M.J., Swann J., Cretney E., Zerafa N., Yokoyama W.M., and Hayakawa Y. NKG2D function protects the host from tumor initiation. J. Exp. Med. 200 (2005) 1325-1335
218. Smyth M.J., Swann J., Kelly J.M., Cretney E., Yokoyama W.M., Diefenbach A., Sayers T.J., and Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200 (2004) 1325-1335
219. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., and Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 18 (2003) 1-6
220. Smyth M.J., Thia K.Y., Cretney E., Kelly J.M., Snook M.B., Forbes C.A., and Scalzo A.A. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162 (1999) 6658-6662
221. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., and Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191 (2000) 661-668
222. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., and Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192 (2000) 755-760
223. Spiotto M.T., Rowley D.A., and Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10 (2004) 294-298
224. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20 (2002) 395-425
225. Steitz J., Bruck J., Lenz J., Knop J., and Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61 (2001) 8643-8646
226. Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., Ganz T., Thoma-Uszynski S., Melian A., Bogdan C., Porcelli S.A., Bloom B.R., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282 (1998) 121-125
227. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
228. Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Rosen-Wolff A., Peters A.M., Sneller M.C., Hallahan C.W., Wang J., Fischer R.E., Jackson C.M., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98 (2001) 194-200
229. Street S.E., Cretney E., and Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001) 192-197
230. Street S.E., Hayakawa Y., Zhan Y., Lew A.M., MacGregor D., Jamieson A.M., Diefenbach A., Yagita H., Godfrey D.I., and Smyth M.J. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199 (2004) 879-884
231. Street S.E., Trapani J.A., MacGregor D., and Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196 (2002) 129-134
232. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183 (1974) 534-536
233. Stutman O. Immunodepression and malignancy. Adv. Cancer Res. 22 (1975) 261-422
234. Stutman O. Chemical carcinogenesis in nude mice: Comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl. Cancer Inst. 62 (1979) 353-358
235. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., and Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 59 (1999) 4516-4518
236. Suranyi M.G., Hogan P.G., Falk M.C., Axelsen R.A., Rigby R., Hawley C., and Petrie J. Advanced donor-origin melanoma in a renal transplant recipient: Immunotherapy, cure, and retransplantation. Transplantation 66 (1998) 655-661
237. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., and Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
238. Svane I.M., Engel A.M., Nielsen M.B., Ljunggren H.G., Rygaard J., and Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur. J. Immunol. 26 (1996) 1844-1850
239. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. Lancet Oncol. 4 (2003) 565-573
240. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., and Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
241. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., Iwakura Y., Yagita H., and Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7 (2001) 94-100
242. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., and Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195 (2002) 161-169
243. Tawara I., Take Y., Uenaka A., Noguchi Y., and Nakayama E. Sequential involvement of two distinct CD4+ regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn. J. Cancer Res. 93 (2002) 911-916
244. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., and Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
245. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003) 1741-1752
246. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., and Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 195 (2002) 99-111
247. Thomas L. Discussion. In: Lawrence H.S. (Ed). "Cellular and Humoral Aspects of the Hypersensitive States" (1959), Hoeber-Harper, New York 529-532
248. Thomas L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55 (1982) 329-333
249. Tieng V., Le Bouguenec C., du Merle L., Bertheau P., Desreumaux P., Janin A., Charron D., and Toubert A. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc. Natl. Acad. Sci. USA 99 (2002) 2977-2982
250. Trapani J.A., and Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2 (2002) 735-747
251. Traversari C., van der Bruggen P., Van den Eynde B., Hainaut P., Lemoine C., Ohta N., Old L., and Boon T. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35 (1992) 145-152
252. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., and Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200 (2004) 771-782
253. Ueda R., Shiku H., Pfreundschuh M., Takahashi T., Li L.T., Whitmore W.F., Oettgen H.F., and Old L.J. Cell surface antigens of human renal cancer defined by autologous typing. J. Exp. Med. 150 (1979) 564-579
254. Uhr J.W., Scheuermann R.H., Street N.E., and Vitetta E.S. Cancer dormancy: Opportunities for new therapeutic approaches. Nat. Med. 3 (1997) 505-509
255. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 1269-1274
256. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J., Zinkernagel R.M., and Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184 (1996) 1781-1790
257. van den Broek M.F., Kagi D., Zinkernagel R.M., and Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25 (1995) 3514-3516
258. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
259. Vetter C.S., Groh V., thor Straten P., Spies T., Brocker E.B., and Becker J.C. Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol. 118 (2002) 600-605
260. Vicari A.P., and Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 13 (2002) 143-154
261. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., Zuil M., and Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35 (2002) 23-28
262. Wang R.F., and Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170 (1999) 85-100
263. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10 (2004) 48-54
264. Westwood J.A., Kelly J.M., Tanner J.E., Kershaw M.H., Smyth M.J., and Hayakawa Y. Cutting edge: Novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J. Immunol. 172 (2004) 757-761
265. Wheelock E.F., Weinhold K.J., and Levich J. The tumor dormant state. Adv. Cancer Res. 34 (1981) 107-140
266. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
267. Wong G.H., Elwell J.H., Oberley L.W., and Goeddel D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58 (1989) 923-931
268. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., Edmondson S., Devenish R.J., and Ralph S.J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 272 (1997) 28779-28785
269. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., and June C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 (2001) 4766-4772
270. Wu G.S., Burns T.F., McDonald III E.R., Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., Hamilton S.R., Spinner N.B., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17 (1997) 141-143
271. Xu X., Fu X.Y., Plate J., and Chong A.S. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58 (1998) 2832-2837
272. Yang L., and Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92 (2004) 13-27
273. Yue H.H., Diehl G.E., and Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 12 (2005) 94-97
274. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
275. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789